ONWARD medical schedules webcast with Q3 2024 updates and year-to-date highlights

Company to provide update on key milestones and near-term plans, including recent successful financing and agreements with Ottobock and CEA

EINDHOVEN, Netherlands, November 12, 2024 (GLOBE NEWSWIRE) — ONWARD Medical NV (Euronext: ONWD), the medical technology company developing innovative spinal cord stimulation therapies to restore movement, function and independence in people with spinal cord injury (SCI) today announces that it will host a webcast to discuss Q3 2024 business highlights.

The webcast will take place on November 26, 2024 at 2:00 PM CET / 8:00 AM ET. The meeting will be hosted by CEO Dave Marver, who will discuss Q3 2024 highlights and provide a business update.

To participate in the webcast via Zoom, you must register via this link.

Participants can also register by telephone:

+32 2 290 9360 (Belgium)

+33 1 7095 0350 (France)

+49 69 3807 9884 (Germany)

+31 20 794 0854 (Netherlands)

+41 22 591 0156 (Switzerland)

+44 203 481 5240 (United Kingdom)

+1 346 248 7799 (USA)

Additional telephone numbers available

Meeting ID: 834 0031 2222

A recording of the webcast will be available on the company’s website following the live event.

Visit ONWD.com to learn more about ONWARD Medical’s commitment to working with the SCI community to develop innovative solutions to restore movement, function and independence after spinal cord injury.

Note: All ONWARD Medical devices and therapies, including but not limited to ARC-IM, ARC-EX, ARC-BCI and ARC Therapy, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. ONWARD, ARC-EX, ARC-IM, ARC-BCI and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.

About ONWARD Medical

ONWARD Medical is a medical technology company developing therapies to restore movement, function and independence in people with spinal cord injury (SCI) and movement limitations. Building on more than a decade of scientific discoveries, preclinical and clinical research conducted at leading hospitals, rehabilitation clinics and neuroscience laboratories, the company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations by the U.S. Food and Drug Administration (FDA). FDA).

ONWARD ARC Therapy is targeted, programmed spinal cord stimulation designed to be delivered by the company’s external ARC-EX or implantable ARC-IM platforms. ARC therapy can also be delivered by the company’s ARC-BCI platform, which couples the ARC-IM system with brain-computer interface (BCI) technology to restore movement after spinal cord injury with thought-guided control.

Use of non-invasive ARC-EX therapy significantly improved upper extremity function after spinal cord injury in the global pivotal Up-LIFT trial, with results published by Naturopathy in May 2024. The company has submitted its regulatory application to the FDA for approval of the ARC-EX system in the US and is preparing to submit to regulatory authorities in Europe. At the same time, the company is conducting clinical trials of its ARC-IM therapy, which demonstrated positive interim clinical results for improved blood pressure control after spinal cord injury. Other ongoing clinical trials focus on the use of ARC-IM therapy to address mobility after spinal cord injury and walking difficulties in Parkinson’s disease, as well as the use of the ARC-BCI platform to improve thought-directed movement of both upper and lower limbs after spinal cord injury.

Headquartered in Eindhoven, Netherlands, ONWARD Medical has a Science and Engineering Center in Lausanne, Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels and Amsterdam (ticker: ONWD).

For more information, visit ONWD.com and connect with us on LinkedIn and YouTube.

For media inquiries:
Aditi Roy, VP Communications
[email protected]

For investor questions:
Amori Fraser, Chief Financial Officer
[email protected]

Disclaimer

Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations and projections of the Company or, as applicable, the Company’s directors about future events. By their nature, forward-looking statements involve various risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. A variety of factors, including, but not limited to, delays in regulatory approvals, changes in demand, competition and technology, could cause actual events, performance or results to differ materially from those anticipated. Forward-looking statements in this press release regarding past trends or activities should not be interpreted as a representation that such trends or activities will continue in the future. Accordingly, the company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements contained in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which such forward-looking statements are based . Neither the Company, its advisors or representatives, nor any of its subsidiaries or the officers or employees of any such persons warrant that the assumptions underlying such forward-looking statements will be free from errors nor do they accept any responsibility for the future accuracy of the forward-looking statements. statements in this press release or the actual occurrence of the predicted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. All ONWARD Medical devices and therapies referenced here, including but not limited to ARC-IM^®ARC-EX^®ARC-BCI™ and ARC Therapy™ are investigational and not available for commercial use.